Gilead Sciences and BioNTech launch Phase 3 trial for TNBC
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
What happened
Gilead Sciences and BioNTech announced a clinical trial collaboration and supply agreement. They will evaluate pumitamig, which is being jointly developed by BioNTech and Bristol-Myers Squibb, in combination with sacituzumab govitecan. This combination is being tested as first-line treatment for patients with locally advanced or metastatic PD-L1 low or negative triple-negative breast cancer in the ROSETTA Breast-01 Phase 3 trial.
From finanznachrichten.de
Why it matters
The collaboration aims to improve outcomes for patients with triple-negative breast cancer. The global Phase 3 trial will evaluate this combination against chemotherapy, potentially establishing a new standard of care for first-line treatment in this specific cancer type.
From finanznachrichten.de
Who's involved
- Gilead SciencesSupplies sacituzumab govitecan and is collaborating on the clinical trial.
- Bristol-Myers SquibbJointly develops pumitamig with BioNTech for the clinical trial.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- ArcellxSpeculative
Arcellx might see increased revenue from securing a supply agreement for sacituzumab govitecan in the new combination trial.